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1044-52 Is There a Relationship Between Stent/Lesion Length 
Ratio and Edge Effect in the Drug-Eluting Stent Era? An 
Intravascular Ultrasound Analysis
Juan S. Muñoz, Alexandre Abizaid, Mariano Albertal, Fausto Feres, Roselei Graebin, 
Andrea S. Abizaid, Luiz A. Mattos, Rodolfo Staico, Galo Maldonado, Amanda Sousa, 
Gary Mintz, J. Eduardo Sousa, Institute Dante Pazzanese of Cardiology, Sao Paulo, 
Brazil, Cardiovascular Research Foundation, New York, NY
Different stent/lesion length ratios (SLLR) have been reported in various multicenter
drug-eluting stent (DES) trials (SIRIUS 1.6 vs. RAVEL 2.2). This may determine the
“uncovered” stent edge plaque burden, which is known to contribute to edge restenosis
after bare metal stents.
Objective: To evaluate whether plaque dynamics at the stent edges differ in relation to
the SLLR.
Methods: Fifty patients with de novo native coronary lesions were successfully treated
with sirolimus-eluting stenting. Patients were divided into two groups according to the
median SLLR of the entire group: group A SSLR <1.79 (n=25) and B >1.79 (n=25). Volu-
metric intravascular ultrasound (IVUS) was performed immediately after the procedure
(Post) and at 6 months follow-up; and the 5-mm proximal and distal edges were ana-
lyzed.
Results: The mean SLLR value of the study population was 1.78±0.19 (range=1.41-
2.20). There were no differences in clinical and lesion characteristics between the two
groups. IVUS analysis is shown below. 
* p=NS vs. Group B. IH= Intimal hyperplasia.
Conclusion: Longer DES in relation to lesion length resulted in less plaque growth at 6-
month follow-up, especially at the proximal edge. This supports the concept of stenting
longer segments when implanting DES.
1044-53 Full Metal Jacket in the Drug-Eluting Stent Era: In-
Hospital and 30-Day Outcome
Dejan Orlic, Goran Stankovic, Nicola Corvaja, Flavio Airoldi, M. Montorfano, D. Tavano, 
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EMO, Cnetro Cuore Columbus, Milano, Italy, San Raffaele Hospital, Mialno, Italy
Background: Full lesion coverage demands use of multiple long stents (Full Metal
Jacket: FMJ) in the same vessel. We examined the safety of this strategy utilizing Cypher
in coronary arteries.
Methods: Patients who received Cypher stents > 66 mm of length in one vessel were
analyzed.
Results: FMJ was utilized in 63 patients and 139 lesions with 187 Cypher stents. Mean
length of 66 FMJ stented segments was 84.8±25.1 mm (range 66-198mm). The 63
patients presented with previous MI (46%), prior CABG (17%), diabetes mellitus (33%)
and unstable angina (16%), 92% had multivessel disease. Among lesions 95% were type
B2 or C, 21% in-stent restenosis and 20% chronic total occlusions. Mean reference diam-
eter was 2.63±0.54 mm, MLD 0.66±0.55 mm and diameter stenosis 74.7±20.2 %. Bal-
loon/artery ratio was 1.18±0.18 and maximal inflation pressure 16.4±3.01 atm. Final
diameter stenosis at the narrowest point of FMJ stented segment was 12.9±8.9%, acute
gain was 2.09±0.92 mm. Glycoprotein IIb/IIIa inhibitors were given electively in 40
patients. Acute thrombosis occurred in 2 patients, despite elective treatment with GP IIb/
IIIa inhibitors in both, and it was successfully treated with thrombolytic therapy in one
(198 mm of FMJ in LAD) and with mechanical thrombectomy in another patient. In hospi-
tal major adverse events manifested in 15 (24%) patients: one patient had Q-wave MI
and other 14 patients had non-Q MI defined as CK-MB elevation three times above the
upper limit of normal range. No repeat PCI, CABG or death occurred in hospital. Thirty-
day clinical follow-up was done in all patients. Two adverse events occurred: one MI 7
days after patient discontinued clopidogrel with death and a subacute thrombosis with
non-Q MI . Conclusion: Full Metal Jacket with Cypher stents is an approach with some
risks. Despite liberal usage of IIb/IIIa inhibitors peri-procedural events were relatively
high.
1044-54 Influence of Vessel Wall Calcium on Neointimal Growth 
Following Bare Metal and Sirolimus-Eluting Stent 
Implantation: A 3-D Intravascular Ultrasound Substudy 
of the SIRIUS Trial
Yoshihisa Shimada, Junya Ako, Brian K. Courtney, Toru Kataoka, Shinjo Sonoda, 
Yoshihiro Morino, Jeffrey W. Moses, Martin B. Leon, Peter J. Fitzgerald, Paul G. Yock, 
Yasuhiro Honda, Stanford University, Stanford, CA, Lenox Hill Hospital, New York, NY
Background: The purpose of this study was to examine the potential influence of vessel
wall calcium on neointimal growth, comparing bare metal stents (BMS) and sirolimus-
eluting stents (SES).
Methods: Calcified segments were defined as those involving cross-sections with a total
calcium arc >120º, and non-calcified segments as those containing no calcium at all.
Among 8-month 3D IVUS follow-up images in the SIRIUS trial, 26 BMS and 25 SES
patients had both calcified and non-calcified segments within the stented lesion. Neointi-
mal volume index (NVI) (volume/stent length) was computed throughout the stent. At the
calcified segment, NVI on the calcified and non-calcified sides were also measured and
circumferentially normalized by their respective arcs (nNVI; NVI per 360°).
Results: In BMS, 17 of 26 pts (65%) showed lower NVI in the calcified segment com-
pared to the non-calcified segment. Within the calcified segment, 18 of 26 pts (69%)
showed lower nNVI on the calcified side compared to the non-calcified side. nNVI was
significantly lower on the calcified side than on the non-calcified side (2.1±1.2 vs. 2.5±1.4
mm3/mm per 360°, p<0.05). In the SES group, NVI was not affected by the presence of
calcium.
Conclusions: These results suggest that calcium deposits may influence neointimal
growth with BMS. Although these results are limited due to the small patient population
and study inclusion criteria, suppression of neointima with SES does not appear to be
affected by the presence of calcium.
1044-55 Overdilation of Cypher 3.0 mm 6 Cells Stent: Clinical 
Consequences
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Purpose. We evaluated the safety and effectiveness of postdilating a 3.0 mm Cypher
stent (6 cells) with a larger balloon in order to overcome the availability of the right size
stent.
Methods. We identified 70 consecutive patients (80 lesions) who underwent percutane-
ous coronary interventions using Cypher stents (84 stents), that had a nominal diameter
of 3.0 mm (6 cells), and were subsequently post-dilated with a balloon >3.5 mm.
Results. All stents were implanted successfully;12 (17%) patients suffered non-Q-wave
myocardial infarction (MI)(defined as CK-MB elevation> 3 times normal) with no other
major in-hospital complications. One- and six-month clinical follow up (mean:14±8
months) was available in all patients:The combined Q-wave MI and death, TLR, and TVR
were 5.7%, 13%, and 14% respectively.Angiographic follow-up was available in 53% (see
Table).
Conclusions. Despite a relatively large reference vessel diameter implantation of a 3.0
mm Cypher stent with postdilation >3.5mm is accompanied by a higher than expected
need for revascularization. Distortion of stent geometry with inhomogeneous drug deliv-
ery could be one reason for these results. Until a dedicated 3.5 mm stent (7 cells)
becomes available it may be better to refrain from implanting a 6 cell Cypher stent in
large vessels. 
Group A(SLLR<1.79; n=25) Group B(SLLR>1.79; n=25)
IVUS results (mm3) Post 6-month P Post 6-month P
Prox. edge-stent lumen 36.0±14.0 39.1±16.7 0.1 32.4±10.2 37.5±18.1 0.2
Prox. edge-stent plaque 31.5±13.6 36.9±15.0 0.004 30.7±12.8 33.8±17.2 0.1
Prox. edge-stent vessel 67.5±20.9 76.0±22.1 0.001 63.1±15.7 71.2±27.7 0.07
Distal edge-stent lumen 34.0±14.3 38.8±18.2 0.1 27.7±9.5 31.8±10.2 0.08
Distal edge-stent 
plaque
21.9±12.8 23.0±13.9 0.3 17.9±10.0 19.7±10.8 0.2
Distal edge-stent vessel 56.0±20.9 61.8±28.2 0.1 45.6±15.4 51.6±14.8 0.2
In-stent IH* - 1.74±5.9 - - 1.34±4.4 -
Preintervention Postintervention Follow-up
RVD (mm) 3.77 ± 0.30 3.89 ± 0.40 3.74 ± 0.43
MLD (mm) 1.27 ± 0.68 3.44 ± 0.47 2.96 ± 0.73
DS (%) 66 ± 18 12 ± 8 22 ± 17
Lesion Length (mm) 17.53 ± 13.05
